Kraig Biocraft Laboratories Announces Successful Launch of Spring Production Trials in Southeast Asia for Spider Silk
April 15, 2024 07:05 ET
|
Kraig Biocraft Laboratories
Kraig Biocraft Labs (OTCQB: KBLB) kicks off new BAM-1 hybrid spring production trials, on track to meet expectations and timeline
Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation
April 15, 2024 04:00 ET
|
Regeneron Ventures
GREENWICH, Conn., April 15, 2024 (GLOBE NEWSWIRE) -- Regeneron Ventures announces its formation as a venture capital fund focused on promising biopharmaceutical, health care and health technology...
BC Platforms and NTT Group Announce Official Opening Ceremony for Exclusive Collaboration and Launch of Japanese Precision Medicine Platform
April 15, 2024 02:00 ET
|
BC Platforms
ZURICH, Switzerland, April 15, 2024 (GLOBE NEWSWIRE) -- BC Platforms (BCP), a global leader in real world data, healthcare data management, and analytics, today announces an exclusive collaboration...
Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health
April 11, 2024 09:45 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has reached an agreement in principle for...
PharmAla Announces Private Placement and Concurrent Debt Settlement
April 10, 2024 16:30 ET
|
PharmAla Biotech
PharmAla Initiates $750,000 Private Placement with concurrent debt settlement, anticipated to close on April 17th 2024
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
April 10, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting
April 09, 2024 16:30 ET
|
Frontier Medicines
- Pre-clinical results demonstrate the combination of FMC-376 with PD-1 immunotherapy increases survival and response rates compared to PD-1 alone - FMC-376 is broadly active in KRASG12C mutant...
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
April 09, 2024 16:30 ET
|
IN8bio, Inc
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
April 09, 2024 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network ...
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
April 08, 2024 16:30 ET
|
Cellectis Inc.
Cellectis announces that preliminary data exploring novel TALEN® editing process in HSPCs will be presented at ASGCT 2024